This page shows the latest ixekizumab news and features for those working in and with pharma, biotech and healthcare.
IL-23-selective follow-up Tremfya (guselkumab) as well as three IL-17 inhibitors - Novartis’ Cosentyx (secukinumab), Eli Lilly’s Taltz (ixekizumab) and Valeant Pharma’s Siliq (brodalumab).
ixekizumab) and Valeant’s Siliq (brodalumab).
Taltz (ixekizumab) was first approved as a treatment for psoriasis in 2016, and the new indication - which was approved in the US in December - is a boost as it plays
to surging sales of diabetes drugs Trulicity (dulaglutide) and Jardiance (empagliflozin) and a near five-fold increase for psoriasis drug Taltz (ixekizumab).
Lilly's first-half revenues rose 8% to $5.8bn thanks to surging sales of new drugs like diabetes therapy Trulicity (dulaglutide) and psoriasis drug Taltz (ixekizumab), and the company is
Also entering a competitive sector was Lilly's new psoriasis drug Taltz (ixekizumab), which nevertheless rocketed to almost $140m in the quarter, while diabetes drug Jardiance (empagliflozin) showed signs of benefiting
More from news
Approximately 2 fully matching, plus 39 partially matching documents found.
Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...